Biocon announces that it has entered into an option agreement with Bristol-Myers Squibb for Biocon’s IN-105, an oral insulin drug candidate…
Biocon to continue development of IN-105 through Phase II; Bristol-Myers Squibb will have an exclusive option to further develop and commercialize IN-105, pending outcome of clinical trials Biocon announced today that it has entered into an option agreement with Bristol-Myers Squibb Company (NYSE: BMY) for Biocon’s IN-105, a prandial oral insulin product candidate. Under the …